Rib-X Pharmaceuticals, Inc. Initiates Delafloxacin Global Phase 3 Clinical Trial in Patients With Acute Bacterial Skin and Skin Structure Infections

Published: May 14, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rib-X Pharmaceuticals, Inc., today announced the initiation of a Phase 3 clinical trial evaluating delafloxacin, the company’s lead antibiotic, in patients with acute bacterial skin and skin structure infections (ABSSSI). Delafloxacin is a novel fluoroquinolone antibiotic with intravenous (IV) and oral formulations that have demonstrated a favorable safety and efficacy profile in prior studies against infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and a broad array of Gram-positive and Gram-negative bacteria, many of which were resistant to other quinolones.

Help employers find you! Check out all the jobs and post your resume.

Back to news